Gambro shareholder Investor rejects sale report:
This article was originally published in Clinica
Swedish investment company Investor has dismissed a report in the Swedish daily newspaper Dagens Industri last week that it was poised to sell its 20% stake in dialysis company Gambro to competitor Baxter. "There is no deal between Investor and Baxter," said Nils Ingvar Lundin, Investor's spokesman. Baxter declined to comment. Last year, the Swedish newspaper published a similar report concerning Gambro and German company Fresenius (see Clinica No 913, p 9).
You may also be interested in...
US FDA will simultaneously review the vaccines, with Moderna’s advisory committee set a week after Pfizer’s. ACIP emergency meeting scheduled for 1 December with vote likely on distribution priority for health care personnel.
Sabinsa provided FDA and FTC with documentation of “an ingredient falsely marketed and sold as vitamin C derived from amla fruit (Emblica officinalis), which two independent labs have confirmed is actually derived from corn, sugarcane or other plants.”
With its US/Mexico Phase III trial delayed due to manufacturing questions, Novavax has aligned its UK study with FDA guidance. It hopes for interim data from that study during Q1 2021.